~~<i id='921590C49A'><strike id='921590C49A'><tt id='921590C49A'><pre id='921590C49A'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

Wikipedia

author：knowledge 2025-08-15 00:51:50 - browse：5425

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： Medicare Advantage isn’t working — for anyone

focus

leisure time

hotspot

knowledge

explore

hotspot

ThisimagereleasedbySonyPicturesshowsPatrickWilsoninScreenGems'"Insidious:TheRedDoor."(SonyPicturesvi

WSS

There should be a 'Moonshot' or 'Warp Speed' for rare diseases

Medicare Advantage isn’t working — for anyone

White House announces new plan to address the growing threat of xylazine in overdose crisis

See Ryan Reynolds, Hugh Jackman suited up in 1st look at 'Deadpool 3': Photo

Biden targets hefty hospital 'facility fees' that often surprise patients

Readout Newsletter: GSK, Viking Therapeutics, mifepristone news

hotspot

Wikipedia

focus

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Biden’s NIH nominee is languishing in Congress

BioMarin wins approval for gene therapy to treat hemophilia A

Study fuels hope CAR

Duchenne breakthrough therapy leaves behind pioneering families

Presidential fundraising highlights so far: Trump brings in more than DeSantis

Sports medicine is finally prioritizing gender equality

The aspartame in Diet Coke probably isn’t giving you cancer

Walensky prepares to leave CDC — and Congress — behind

Eisai exec who led development of Alzheimer’s drug to retire

leisure time

Tulsa Race Massacre survivors and attorneys respond to dismissal of lawsuit

Bank of America ordered to pay more than $100 million for double charging fees, withholding rewards

STAT Madness 2024: Meet the contenders

The U.S. needs a new definition of substance use “recovery”

Study fuels hope CAR

Biden’s NIH nominee is languishing in Congress

hotspot

knowledge

explore

hotspot